Purpose: To assess the characteristics and prevalence of fundus abnormalities in vitreoretinal lymphoma (VRL) using multimodal imaging. Methods: We retrospectively reviewed chart and imaging studies of patients diagnosed with VRL. Results: All 10 VRL patients (14 eyes) included in the study showed vitreitis, hyperreflective lesions on near-infrared reflectance imaging, and hypoautofluorescent lesions on fundus autofluorescence. Other findings included hypofluorescent lesions on fluorescein angiography (79%), hypocyanescent lesions on indocyanine green angiography (77%), small retinal pigment epithelium detachments (PEDs) (71%) and large PEDs (36%) on optical coherence tomography (OCT). Outer retinal layer nodularity was identified on OCT in 93% of cases. Small PEDs corresponded to hyperreflective, hyperautofluorescent, hypofluorescent, hypocyanescent lesions. Conclusion: Multiple signs were present on multimodal imaging in VRL eyes. Lymphomatous infiltration created focal PEDs showing abnormal imaging signals. Outer retinal layer nodularity could represent an additional sign of infiltration. Multimodal imaging may guide physicians in the early diagnosis of VRL.

Keywords:
Primary intraocular lymphoma, Vitreoretinal lymphoma, Lymphoma, Multimodal imaging
1.
Chan CC, Rubenstein JL, Coupland SE, et al: Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist 2011;16:1589-1599.
2.
Coupland SE, Damato B: Understanding intraocular lymphomas. Clin Experiment Ophthalmol 2008;36:564-578.
3.
Chan CC, Buggage RR, Nussenblatt RB: Intraocular lymphoma. Curr Opin Ophthalmol 2002;13:411-418.
4.
Coupland SE, Heimann H, Bechrakis NE: Primary intraocular lymphoma: a review of the clinical, histopathological and molecular biological features. Graefes Arch Clin Exp Ophthalmol 2004;242:901-913.
5.
Sagoo MS, Mehta H, Swampillai AJ, et al: Primary intraocular lymphoma. Surv Ophthalmol 2014;59:503-516.
6.
Ishida T, Ohno-Matsui K, Kaneko Y, et al: Fundus autofluorescence patterns in eyes with primary intraocular lymphoma. Retina 2010;30:23-32.
7.
Levasseur SD, Wittenberg LA, White VA: Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes. JAMA Ophthalmol 2013;131:50-55.
8.
Casady M, Faia L, Nazemzadeh M, et al: Fundus autofluorescence patterns in primary intraocular lymphoma. Retina 2014;34:366-372.
9.
Fardeau C, Lee CP, Merle-Beral H, et al: Retinal fluorescein, indocyanine green angiography, and optic coherence tomography in non-Hodgkin primary intraocular lymphoma. Am J Ophthalmol 2009;147:886-894, 894.e1.
10.
Velez G, Chan CC, Csaky KG: Fluorescein angiographic findings in primary intraocular lymphoma. Retina 2002;22:37-43.
11.
Bartsch DU, Weinreb RN, Zinser G, Freeman WR: Confocal scanning infrared laser ophthalmoscopy for indocyanine green angiography. Am J Ophthalmol 1995;120:642-651.
12.
Liu TY, Ibrahim M, Bittencourt M, et al: Retinal optical coherence tomography manifestations of intraocular lymphoma. J Ophthalmic Inflamm Infect 2012;2:215-218.
13.
Yeh S, Wilson DJ: Combination intravitreal rituximab and methotrexate for massive subretinal lymphoma. Eye (Lond) 2010;24:1625-1627.
14.
Kim E, Kim C, Lee J, Cho Y: A case of primary intraocular lymphoma treated by intravitreal methotrexate. Korean J Ophthalmol 2009;23:210-214.
15.
Saleh M, Nikolitch K, Bourcier T, et al: Repeated IL-10 measurement in aqueous humor and OCT imaging are valuable tools to monitor intraocular lymphoma treated with intravitreal injections of methotrexate. Graefes Arch Clin Exp Ophthalmol 2012;250:761-764.
16.
Liang F, Barale PO, Hoang Xuan K, et al: Subretinal lymphomatous infiltration in primary intraocular lymphoma revealed by optical coherence tomography. Graefes Arch Clin Exp Ophthalmol 2011;249:1425-1427.
17.
Kimura K, Usui Y, Goto H; Japanese Intraocular Lymphoma Study Group: Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma. Jpn J Ophthalmol 2012;56:383-389.
18.
Egawa M, Mitamura Y, Hayashi Y, Naito T: Spectral-domain optical coherence tomographic and fundus autofluorescence findings in eyes with primary intraocular lymphoma. Clin Ophthalmol 2014;8:335-341.
19.
Forooghian F, Merkur AB, White VA, et al: High-definition optical coherence tomography features of primary vitreoretinal lymphoma. Ophthalmic Surg Lasers Imaging 2011;42 Online:e97-e99.
20.
Ezon IC, Barteselli G, Rosenberg J, Freeman WR: Concurrent primary vitreoretinal and spinal cord lymphoma: a unique entity. JAMA Ophthalmol 2014;132:902-904.
21.
Jang HS, Sepah YJ, Sophie R, et al: Longitudinal spectral domain optical coherence tomography changes in eyes with intraocular lymphoma. J Ophthalmic Inflamm Infect 2013;3:59.
22.
Grimm SA, McCannel CA, Omuro AM, et al: Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report. Neurology 2008;71:1355-1360.
23.
Whitcup SM, Stark-Vancs V, Wittes RE, et al: Association of interleukin 10 in the vitreous and cerebrospinal fluid and primary central nervous system lymphoma. Arch Ophthalmol 1997;115:1157-1160.
24.
Turaka K, Bryan JS, De Souza S, et al: Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution. Clin Lymphoma Myeloma Leuk 2012;12:412-417.
25.
Cassoux N, Merle-Beral H, Leblond V, et al: Ocular and central nervous system lymphoma: clinical features and diagnosis. Ocul Immunol Inflamm 2000;8:243-250.
26.
Shields JA, Shields CL: Primary intraocular lymphoma; in Intraocular Tumors: An Atlas and Textbook, ed 2. Philadelphia, Lippincott Williams Wilkins, 2008.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.